Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zilovertamab vedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zilovertamab vedotin overview
Zilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), non-squamous non-small-cell lung cancer, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, or Richter transformation lymphoma, Burkitt lymphoma, lymphoplasmacytoid lymphoma, Waldenström macroglobulinemia, T-cell non-Hodgkin lymphoma, acute lymphoid leukemia, or acute myeloid leukemia, estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, or human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), ovarian cancer and pancreatic cancer. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Zilovertamab vedotin’s drug-specific PTSR and LoA scores, buy the report here.